LATIN AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028

Description

MARKET OUTLOOK

CRI’s research report insinuates that the Latin American companion diagnostics market is expected to register growth at a compound annual growth rate of 12.10% during the forecasting years 2022-2028. Mexico, Brazil, and Rest of Latin America are considered in the region.
In Mexico, initiatives undertaken to reduce approval time for clinical trials are anticipated to surge the adoption of companion diagnostics devices. For instance, the government amended various acts to accelerate clinical trials. Besides this, the Federal Commission for the Protection against Sanitary Risk is working on various aspects to decrease the hurdles faced during these trials. Moreover, it aims to increase the number of pharmaceutical companies conducting clinical trials. Thus, these factors are expected to contribute to the expansion of the companion diagnostics market.
In Rest of Latin America, countries like Argentina, Peru, Chile, and Columbia are expected to witness consistent growth over the forecast period. As per estimates, the in-vitro and molecular diagnostics industry is expanding at a rapid pace, which is estimated to augment the companion diagnostics market’s growth. In Argentina, the rising acceptance of advanced diagnostic technologies by physicians is among the major factors supporting the studied market’s growth.

COMPETITIVE OUTLOOK

The notable companies in the companion diagnostics market include Almac Group, Biocartis, Abbott Laboratories, Danaher Corporation, and GE Healthcare.

TABLE OF CONTENTS

1. LATIN AMERICA COMPANION DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY INSIGHTS
2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS
2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY & SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.10. MARKET DRIVERS
2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING PREVALENCE OF PRECISION MEDICINES
2.11. MARKET CHALLENGES
2.11.1. WEAK REIMBURSEMENT FRAMEWORK
2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET OPPORTUNITY
2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. LATIN AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY MECHANISM
3.1. IN-SITU HYBRIDIZATION
3.2. POLYMERASE CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT GENERATION SEQUENCING
3.5. OTHER MECHANISMS
4. LATIN AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS DISEASES
4.4. OTHER INDICATORS
5. LATIN AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY CONSUMER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE LABORATORIES
5.3. OTHER CONSUMERS
6. LATIN AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY COMMODITY
6.1. ASSAY KITS AND REAGENTS
6.2. SOFTWARE AND SERVICES
7. LATIN AMERICA COMPANION DIAGNOSTICS MARKET – COUNTRY OUTLOOK
7.1. BRAZIL
7.2. MEXICO
7.3. REST OF LATIN AMERICA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT LABORATORIES
8.2. ALMAC GROUP
8.3. ARUP LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER CORPORATION
8.7. GE HEALTHCARE
8.8. GENOMIC HEALTH
8.9. ILLUMINA INC
8.10. MYRIAD GENETICS
8.11. QIAGEN
8.12. ROCHE DIAGNOSTICS
8.13. SYSMEX CORPORATION
8.14. THERMO FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF CANCER PATIENTS IN 2020
TABLE 7: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: BRAZIL COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: MEXICO COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: REST OF LATIN AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)